SARM1 Inhibitors Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
SARM1 Inhibitors Market is segmented By Indication (Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Peripheral Neuropathies, Glaucoma) By Type of Molecule (Small Molecules, Biologics), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Million) for the above-mentioned segments.
SARM1 Inhibitors Market Size
Market Size in USD
CAGR103.7%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 103.7% |
| Market Concentration | Medium |
| Major Players | Disarm Therapeutics, Nura Bio, Washington University, Asha Therapeutics, UCB Pharma |
please let us know !
SARM1 Inhibitors Market Analysis
The SARM1 Inhibitors Market is estimated to be valued at USD 5 Mn in 2024 and is expected to reach USD 727 Mn by 2031, growing at a compound annual growth rate (CAGR) of 103.7% from 2024 to 2031.
The market is expected to witness positive growth over the forecast period. Factors such as high prevalence of neurological disorders such as spinal cord injuries and growing research & development for new drug molecules are expected to drive the demand. Promising clinical trial results of SARM1 inhibitors in treating various neurological conditions will further provide impetus to the growth. Additionally, rising geriatric population prone to neurological diseases complemented with increasing healthcare expenditures is anticipated to support the revenue generation.